You are here

Memorial Sloan-Kettering Cancer Center

1275 York Avenue
New York, NY 10065
United States

Mentor Name: Oriana Miltiadous

Memorial Sloan-Kettering Cancer Center

Mentor Name: Julia Glade-Bender

Memorial Sloan-Kettering Cancer Center

Mentor Name: Nai-Kong Cheung

Memorial Sloan-Kettering Cancer Center

Desmoplastic small round cell tumor (DSRCT) is one of the most aggressive pediatric sarcomas with a low survival rates despite the combination of aggressive chemotherapy, surgery, and radiation therapy. No targeted treatments are currently available and little is known about the biology of this tumor type. Although all patients harbor a very specific chromosomal rearrangements that generates a novel fusion gene, how this gene induces the development of cancer remains a mystery.

The gut microbiome plays a critical role in modulating the immune response, influencing outcomes of allogeneic transplantation, a life-saving treatment for relapsed/refractory leukemia and lymphoma. However, this treatment comes with significant complications that can limit is efficacy. Understanding and leveraging the immunomodulatory potential of the microbiome is crucial for optimizing cancer therapy outcomes. However, the mechanisms underlying the microbiome's influence on outcomes post-transplant, especially in pediatric patients, remain insufficiently understood.

Ewing sarcoma occurs in the bone and soft tissue and represents a substantial fraction of cancers affecting children and adolescents. Ewing sarcoma patient’s outcome has substantially improved with the introduction of chemotherapy, and with the current combination of cytotoxic therapy, radiotherapy, and surgical resection, the 5-year survival approaches 70% for some patients. Unfortunately, intensive treatment increases the risk of long-term health problems, including the development of therapy-associated secondary tumors.

Mentor Name: Oriana Miltiadous

Pages